Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0684249 (lung carcinoma)
 23,830 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Immunopotentiated rats, which were injected with Propionibacterium acnes or BCG, had the 50% survival twice as long as those in untreated controls after intravenous inoculation of Sato lung carcinoma (SLC) cells. The amount of labeled tumor cells in the lung of the adjuvant-treated rats decreased significantly in the first 20 hr after intravenous injection of 51Cr-labeled tumor cells compared to that of control animals. The elevated activities of ATPase and acid phosphatase in the whole nucleated spleen cells as well as spleen lymphocytes separated by Ficoll-Conray gradient were also demonstrated in adjuvant-treated groups. These data suggested that the elevation of ATPase and acid phosphatase activities in nucleated spleen cells as well as spleen lymphocytes has an important role for the suppression of tumor growth in adjuvant-treated rats.
 ...
PMID:Effect of Propionibacterium acnes or BCG on enzyme activities in spleen lymphocytes of Donryu strain rats. 14 84

Effect of BCG, coenzyme Q10, or their combination on ATPase activity in spleen lymphocytes of tumor-bearing rats was investigated in relation to changes in the content of individual coenzyme Q homologs in these cells. Contents of both coenzyme Q9 and Q10 in spleen lymphocytes significantly decreased in the late stage of Donryu rats bearing Sato lung carcinoma. Oligomycin-sensitive ATPase activity in spleen lymphocytes was also significantly depressed in this stage. The depressed, oligomycin-sensitive ATPase activity was significantly recovered by a 3-time intramuscular administration of coenzyme Q10 emulsified with ethanol and saline, and the decreased contents of coenzymes Q9 and Q10 were slightly restored by this treatment. This enzyme activity was also significantly recovered by an intravenous administration of BCG, and was elevated more by the combined treatment with BCG and the emulsified coenzyme Q10. These results suggest that the combined treatment with BCG and emulsified coenzyme Q10 can contribute to the improvement of the depressed bioenergetics in lymphocytes of tumor-bearing animals, and that this combined effect of BCG and emulsified coenzyme Q10 might be based on the combination of their individual activating effect on lymphocytes.
 ...
PMID:Combined effect of BCG and coenzyme Q10 on ATP-ase activity and coenzyme Q content in spleen lymphocytes of tumor-bearing rats. 15 9

One hundred and seven patients with carcinoma of the lung underwent immunologic testing, and 62 of these patients were randomized to an immunotherapy protocol comparing the effects of Pasteur strain BCG, either alone or combined with allogeneic tumor cells, to the effects of no immunotherapy. Patients with residual disease left at the time of surgery or with metastatic disease at the time of diagnosis showed no increase in survival as a result of this form of immunotherapy. An insufficient number of patients with less advanced disease, in whom we would expect the most beneficial effect, have been entered in this study. In general, we were unable to document substantial effects of immunotherapy on the immunologic parameters tested. Only in recall antigen skin testing was there a statistically significant increase in reactivity in the immunotherapy groups. Tests of general immune status appeared to have a predictive value in monitoring lung cancer patients. Anergic patients had a poorer prognosis than did patients who demonstrated skin test reactivity. Patients with normal percentages of lymphocytes (T cells) forming rosettes with sheep erythrocytes at 29 degrees C were generally normal in other tests of immune competence. In serial studies of rosette formation, all patients who developed recurrent disease had a pattern of depressed or falling rosette values, and these abnormalities occurred an average of 3.1 months prior to clinical detection of recurrence. Patients with large-cell anaplastic carcinoma were found to have a significantly higher incidence of depressed rosette levels than the other histologic types. Both large and small-cell anaplastic patients had significantly depressed lymphocyte proliferation by mitogens and allogeneic cells. Although lung cancer patients have been described as immunologically depressed, they are capable of recognizing tumor-associated antigens. When tested in leukocyte migration inhibition assays with tumor-associated antigens, the majority of the patients in our study were found to be reactive. The use of a 3 M KCl extract of pleural effusion cells from a patient with pulmonary adenocarcinoma has given good reactivity and specificity in lung cancer patients of all histologic types. In addition, these patients have been shown to respond in a mixed lymphocyte/tumor interaction to tumor-associated antigens (Dean, 1976b).
 ...
PMID:Immunological monitoring and immunotherapy in carcinoma of the lung. 18 17

Fifty eight patients with small cell carcinoma of the lung were treated with a combined-modality regimen: chemotherapy with adriamycin, cyclophosphamide, and vincristine; BCG immunotherapy; radiotherapy to the lung primary and prophylactic cranial irradiation. Ninteen patients had limited disease, and 39 had extensive disease. There were 27 (48%) partial remissions and 23 (41%) complete remissions, and median survival was 51 wk. Initial performance status and extent of disease had a definite effect on survival. Only 1 patient developed CNS metastases on prophylactic cranial irradiation. Five of 19 patients (26%) with limited disease remain alive and in complete remission at 26-45+ mo. It is becoming clear from this and other recent studies that we can significantly prolong median survival in small cell lung cancer. However, even more important is the fact that limited-extent small cell lung cancer may be a potentially curable disease.
 ...
PMID:Long-term results in combined-modality treatment of small cell carcinoma of the lung. 21 42

BCG (Glaxo) (0.5 ml = 5 X 10(6) organisms) was given subdermally to 250 patients ten days after resection of a lung carcinoma to stimulate the immune system. Increased activity of lymphocytes and macrophages could possibly result in the destruction of small extrapulmonary tumour deposits that were previously unidentified. The two-year survival of this group of patients was compared with 250 controls not receiving BCG after operation. A comparative analysis of the sex, histological types, and lymph node involvement in relation to the survivals occurring in these two groups showed that the administration of BCG by the method described produced a numerically greater survival rate, which was particularly noticeable in the women. None of these figures, however, is statistically significant. It would be unwise to draw any final conclusion until a five-year survey has been completed.
 ...
PMID:Use of BCG as an immunostimulant after resection of carcinoma of the lung: a two-year assessment of a trial of 500 patients. 39 88

The effect of pyran copolymer, injected into mice bearing the M109 Madison lung carcinoma, on serum concentrations of lysozyme, beta-glucuronidase, and N-acetyl-beta, D-glucosaminidase was studied and compared with that of other immunoadjuvants. Increases in lysozyme levels ranging from 50 to 100% were observed after injection of pyran, BCG and Bru-Pel; increases in the levels of the other enzymes were less consistent. Other immunoadjuvants were less effective in raising serum concentrations of lysosomal enzymes. The findings were correlated with the results of previous studies on macrophage activation and antineoplastic action produced by these immunoadjuvants and suggest that serum levels of lysozyme can serve as indices of these effects.
 ...
PMID:Effect of macrophage activation by immunoadjuvants on serum levels of lysosomal hydrolases in mice. 55 9

Sixty consecutive surviving patients treated with subdermal BCG (5 X 10(6) organisms) have been followed up for five years after resection of lung carcinoma. A control group of the previous 60 consecutive surviving patients not treated with BCG was similarly studied. We found no statistical evidence that the administration of BCG by the method described influenced the five-year survival rate, nor has any effective action upon involved lymph nodes or small metastases been demonstrated.
 ...
PMID:Use of BCG as an immunostimulant in the surgical treatment of carcinoma of lung: a five-year follow-up report. 66 85

Disorders of the respiratory tract account for about 13 percent of overall mortality in Switzerland, for about 50 percent of all hospital admissions and for about 7 percent of the nursing days. Cases of obstructive respiratory disease, pneumonia and carcinoma of the lung predominate. Morbidity regarding newly discovered cases of tuberculos is still 0.5 percent and 40 percent of the population are still positive reactors. BCG vaccination of newborns and of all tuberculin-negative schoolchildren is the approved prophylactic procedure. Periodic mass radiography of adults on a voluntary basis, aimed at the early diagnosis of pulmonary disorders, shows an incidence of 0.4/1 000 and of 0.3/1 000 for new cases of tuberculosis and lung cancer respectively. Cases of chronic obstructive respiratory disease who require hospitalization for above-average length and are frequently on sick leave present special sociomedical problems.
 ...
PMID:[Epidemiological and socio-medical problems assoicated with respiratory disorders in Switzerland (author's transl)]. 69 52

The effect of syngeneic tumor cell mixed with BCG on intradermal tumor growth and on specific tumor immunity was evaluated. (1) With the use of several early transplant generations of syngeneic mouse tumors, the ratio of 1:10 to 1:20 of tumor cell--BCG was confirmed as the best for the present mouse--tumor system. (2) The development of immunity capable of eradicating distant tumor deposit was tested by varying doses of tumor deposit inoculated at the same time as the mixture of tumor cell--BCG. The remarkable efficacy of the tumor cell-BCG mixture on local tumor suppression (7/8) and tumor immunity (5/7) was proved with tumor burden of 10(5) cells or less. Control mice receiving BCG contralateral to the tumor site (10(5)) were not able to achieve tumor immunity (1/8), but were able to reject the local tumor (8/8). (3) The tumor cell--BCG mixture was as effective in a line of rat lung carcinoma as it was in the mouse system in rejecting both the local tumor and the tumor challenge injected intramuscularly. (4) Intratumor injection of BCG or nonliving BCG preparation (in which whole cell wall of BCG is attached to oil droplets) in primary tumors in mice previously sensitized with BCG led to a few instances of complete tumor regression in animals having tumor nodules of 3 to 10 mm in diameter. The survival period of animals treated with BCG or with nonliving BCG preparation was significantly longer than that of saline-treated controls.
 ...
PMID:Immunotherapy of cancer: induction of tumor immunity with a mixture of tumor cell-BCG, and the effect of intratumor injection of BCG and of nonliving BCG preparation. 122 16

Systemic administration of the synthetic immunopotentiator pyran, was as effective as the use of the biologic immunopotentiator BCG in activating macrophages and in inhibiting the Lewis lung carcinoma and MCA 2182 sarcoma. Several other synthetic polyanions also activated macrophages and exhibited some anti-tumor activity, but none were as effective as pyran. Cell-wall fractions such as the Ribi vaccine and MER were considerably less effective than BCG. The anti-tumor activity of pyran against the virtually non-immunogenic Lewis lung carcinoma involved non-specifically activated macrophages, and both anti-tumor activity and macrophage activating ability persisted over a 100-fold range of drug from 0.5 mg/kg to 50 mg/kg. The ability of activated macrophages to destroy tumor cells was abrogated by treatment with trypan blue, an inhibitor of macrophage lysosomal enzymes. In addition, preincubation of tumor cells with activated peritoneal cells at effector-cell:target-cell ratios of 20:1 and 5:1 markedly decreased tumor incidence and mortality. Glycogen-stimulated or unstimulated peritoneal cells were completely inactive in inhibiting tumor growth in vivo or exhibiting cytotoxicity in vitro, demonstrating the requirement for activated macrophages selective for tumor-cell destruction.
 ...
PMID:Macrophage activation and anti-tumor activity of biologic and synthetic agents. 124 2


1 2 3 Next >>